Sakar Healthcare Limited

SAKAR.NS

Drug Manufacturers - Specialty & Generic · Healthcare

Price

₹899.50

-13.10 (-1.44%)

Market Cap

₹19.74B

Exchange

National Stock Exchange of India

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Aug 24, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Exceptional

Cash Flow

Good

Stability

Mixed

Valuation

Good

Track this stock — start free trial

Share count rising — dilution

+47.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 15.1M (2022) → 22.3M (2026)

Winston Score History

The full picture

Sakar Healthcare is an Indian pharmaceutical company that makes and sells generic medicines, mainly in injectable and liquid dosage forms. Its products include antibiotics, pain relievers, vitamins, and other essential drugs used by hospitals, clinics, and pharmacies. The company is known as a significant manufacturer of sterile injectables in India.

Sakar earns revenue by manufacturing pharmaceutical products both under its own brand and on a contract basis for other drug companies. It operates primarily out of manufacturing facilities in Gujarat, India, and exports to markets across Africa, Asia, and other emerging regions. Growth depends on expanding its export reach and adding new product approvals, but the company faces risks from intense price competition in the generic drug market and regulatory scrutiny of manufacturing standards.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+41.5% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+87.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

₹0/ year

↓ Declining (-100% vs prior year)

0.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

79.7%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

₹6M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Sakar Healthcare Limited grew revenue 42% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

27.9%

Modest — 27.9% gross margin

Profit after running costs

Operating Margin

20.2%

Excellent — 20.2% operating margin

Return on the money invested

ROCE

16.3%

Strong — 16.3% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+43.8%

Fast-growing sales (+43.8% YoY)

Profit growth

EPS YoY

+80.3%

Earnings growing fast (+80.3% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

85%

Modest — 85% of profit becomes cash

Spare cash per sale

FCF Margin

1.2%

Thin free cash flow (1.2%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

7.16x

Adequate interest coverage (7.2x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

55.4x

Expensive — P/E 55.4

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+16.0

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (55.4 → 39.5)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial